<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-6-55-a</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-6-7-10</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Metabolic and Toxic Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Methylglutaconic Aciduria</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>07</month>
<year>1992</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>07</month>
<year>2016</year>
</pub-date>
<volume>6</volume>
<issue>7</issue>
<fpage>55</fpage>
<lpage>55</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1992 The Author(s)</copyright-statement>
<copyright-year>1992</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="pmid" xlink:href="1594352" vol="89" page="1080">
<article-title>3-Methylglutaconic aciduria: a new variant</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>Two siblings with 3-methylglutaconic aciduria with normal enzyme activity and neurological abnormalities are reported from the Department of Pediatrics, Beilinson Medical Center, Petah Tiqva, Sackler School of Medicine, Tel Aviv University, Israel.</p>
</abstract>
<kwd-group>
<kwd>3-Methylglutaconic Aciduria</kwd>
<kwd>Optic Discs Atrophied</kwd>
<kwd>Brain Atrophy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Two siblings with 3-methylglutaconic aciduria with normal enzyme activity and neurological abnormalities are reported from the Department of Pediatrics, Beilinson Medical Center, Petah Tiqva, Sackler School of Medicine, Tel Aviv University, Israel. Patient 1, an 11 month old infant was referred for evaluation of deterioration of motor development beginning at 5 months of age. There was an arrest of weight gain and head circumference growth. He was restless and had choreoathetoid movements of hands, head and mouth, deep tendon reflexes were hyperactive, plantar responses were extensor and optic discs atrophied. At 2 years of age he sat with support, crawled and walked with help. MRI and CT showed prominent frontal lobe atrophy. Urinary organic acid analysis showed a prominent peak of 3-methylglutaconic and 3-methylglucrylic acid. Patient 2, the 14 year old sister of patient 1, developed ataxia of gait at age 2 years, and optic atrophy at 8 years of age. Examination showed variable muscle tone with brisk tendon reflexes and extensor plantar responses. Choreoathetoid movements were prominent in the upper limbs, head and mouth and funduscopic examine showed prominent optic atrophy. Her IQ on the WISC was 87. CT and MRI showed generalized brain atrophy. Urinary organic acid excretion showed a prominent peak of methylglutaconic and methylglutaric acids. The patients represent a new clinical variant of the methylglutaconic aciduria syndrome with a relatively favorable prognosis. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<disp-quote>
<p><bold>COMMENT.</bold> 3-Methylglutaconic aciduria is the hydrolysis product of 3-methylglutaconyl coenzyme and an intermediate in the degradation pathway of leucine. Two syndromes are described - one with deficient methylglutaconyl coenzyme A and the other with normal enzyme activity, but prominent neurological deterioration. The present case reports were unique in the relatively normal cognitive and intellectual development and the relatively mild neurological manifestations. The boy had demonstrated developmental improvement in his second year of life and his sister developed well with normal school performance.</p>
</disp-quote>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeharia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elpeleg</surname>
<given-names>ON</given-names>
</name>
<name>
<surname>Mukamel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ariel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mimouni</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>3-Methylglutaconic aciduria: a new variant</article-title>
<source>Pediatrics</source>
<year>1992</year>
<month>Jun</month>
<volume>89</volume>
<issue>6 Pt 1</issue>
<fpage>1080</fpage>
<lpage>1082</lpage>
<pub-id pub-id-type="pmid">1594352</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>